Introduction
============

In recent years gender and sex differences in pain recognition and drug responses have been extensively investigated both in clinical trials and experimental models of pain. Despite a large number of epidemiological studies clearly reveal that women report pain more frequently than men ([@B81]; [@B8]; [@B68]; [@B29]), results obtained in rodents are not always consistent and often depend on the type of pain and treatment protocol ([@B24]; [@B61]). More recently, it has been demonstrated that the immune system differently mediates pain hypersensitivity in male and female rodents ([@B77]) thus emphasizing the need to elucidate mechanisms underlying sex differences in pain responses with the aim to support the development of gender-specific drug therapies.

Different classes of antidepressant drugs are clinically effective in various forms of chronic pain including arthritis, diabetic neuropathy, post-herpetic neuralgia, migraine, fibromyalgia, low back pain ([@B33]). Antidepressant drugs act by blocking the norepinephine and/or serotonin transporter on presynaptic site enhancing the descending inhibitory control on pain ([@B60]; [@B10]; [@B59]). Nevertheless, many other mechanisms can account for their analgesic activity involving sodium and calcium channels or a number of receptors including GABAB, opioid, and adenosine receptors ([@B26]). In this regard the activity as sodium and calcium blockers as well as the ability to decrease prostaglandin E2 production elicited by several antidepressants including fluoxetine, has been proposed as an important mechanism to explain the efficacy of antidepressants as analgesics ([@B26]).

In clinical practice, it is generally accepted that the tricyclic antidepressant (TCA), amitriptyline, and the serotonin/noreprinephine reuptake inhibitor (SNRI), duloxetine, are effective in persistent pain ([@B4]; [@B30]). However, there is less agreement about the efficacy of antidepressants belonging to the selective serotonin reuptake inhibitor (SSRI) class ([@B75]; [@B70]; [@B31]). Only few studies have demonstrated some efficacy of SSRIs such as paroxetine and citalopram but not fluoxetine in painful diabetic neuropathy ([@B74], [@B73]; [@B55]). On the other hand, in a number of trials that included almost exclusively women, the SSRI fluoxetine, has been shown to be effective in chronic tension-type headache ([@B84]) and in the treatment of fibromyalgia ([@B14]; [@B86]; [@B34]; [@B2]), a musculoskeletal condition characterized by chronic widespread pain and muscle tenderness with a high prevalence on women compared to men ([@B87]).

In rodents the analgesic activity of antidepressant drugs has been evaluated both in models of acute and persistent pain. Most of the studies have been performed with high dose of antidepressants acutely injected ([@B11]; [@B63]). We have previously shown that fluoxetine is also effective in the formalin test after a single intraperitoneal injection and that the analgesic activity is lost in *Lmx1b* conditional knock-out mice (*Lmx1b^f/f/p^*), which lack 5-HT neurons in the central nervous system ([@B94]). However, protocols of acute treatment do not reproduce the clinical use of these drugs.

Based on these pieces of evidence, we sought to investigate whether a long-term administration with fluoxetine might have sex-specific effects in pain behavior in mice. Moreover, antidepressant treatment may induce direct epigenetic effects and fluoxetine itself is known to modulate the expression of epigenetic modifying enzymes ([@B66]; [@B58]; [@B96]; [@B57]; [@B27]; [@B82]).

Epigenetic modifications, including DNA methylation and changes of chromatin structure and function, are the most common mechanisms that control gene expression and, eventually, influence protein expression levels. DNA methylation involves direct chemical modification to the DNA, through the addition of a methyl group at the 5′ position of cytosines in CpG dinucleotides, and usually mediate repression of gene transcription ([@B62]). On the other hand, a number of post-translational modifications of chromatin structure, including acetylation, methylation, phosphorylation may either increase and repress gene expression ([@B12]). In particular, acetylation is regulated by two classes of enzymes, histone acetyltransferases (HATs) and deacetylases (HDACs) that, respectively, promote acetylation and deacetylation of lysine tails in histone proteins ([@B51]).

We have first demonstrated that HDAC inhibitors produce analgesic effects via the upregulation of metabotropic glutamate receptor type-2 (mGlu2), an inhibitory receptor whose activation mediates analgesic effects in different pain models ([@B22]). Different HDAC proteins have been identified and subdivided in four classes (I, II, III, and IV) according to their structure, cellular localization and function ([@B72]). Class I includes HDAC1, HDAC2, HDAC3, and HDAC8. Class II consists of six HDAC proteins that include HDAC4, HDAC5, HDAC6 HDAC7, HDAC9 and HDAC10, while HDAC11 belongs to class IV. Differently to the other HDAC proteins, class III HDACs operate by a NAD^+^-dependent mechanism and are referred to as sirtuins (SIRT1-7) ([@B36]). However, among HADACs, the HDAC2 is the only isoform that has been shown to regulate the expression of mGlu2 receptors ([@B48]) and fluoxetine itself is known to modulate the expression of HDAC2 ([@B28]).

With this in mind, we tested whether a chronic treatment with fluoxetine induces sex specific analgesic effects in the mouse formalin test. We also and evaluated HDAC2 and mGlu2 receptor expression in DRG and dorsal horn by western blot and immunohistochemistry analysis.

Results
=======

Chronic Treatment with Fluoxetine Reduces the Second Phase of the Formalin Test in Female Mice
----------------------------------------------------------------------------------------------

Fluoxetine (10 mg/Kg) was intraperitoneally injected in adult male and female littermates for 21 days and pain behavior was evaluated in the mouse formalin test. The intraplantar (i.pl.) injection of a dilute solution of formalin (10 μl, 5%) induces a biphasic response, namely phase I and phase II, characterized by the flinching, lifting, and licking of the injected paw. The first phase starts immediately after the formalin injection and lasts about 10 min. This phase represents an acute form of pain response deriving from the direct activation of nociceptors. Conversely, the second phase that starts after 10 min from the formalin injection, represents a tonic form of pain deriving from the establishment of an inflammatory response sustained by mechanisms of central sensitization in the dorsal horn of the spinal cord ([@B23]; [@B80]). As reported in **Figure [1](#F1){ref-type="fig"}**, there was no statistical difference in the formalin test between vehicle treated male and female mice (**Figures [1A,B](#F1){ref-type="fig"}**). However, while repeated fluoxetine administration did not affect formalin behavior in male mice (**Figure [1A](#F1){ref-type="fig"}**) in both phases, the second phase of the formalin test was significantly reduced in female mice (**Figure [1B](#F1){ref-type="fig"}**), suggesting a sex-dependent analgesic effect of chronic fluoxetine.

![Effects of chronic administration with fluoxetine in the formalin test in male and female CD1 mice. Chronic administration with fluoxetine (10 mg/Kg, i.p. for 21 days) fails to induce analgesia in male mice **(A)** but reduces the second phase of the formalin test in female CD1 mice **(B)**. Data are means ± SEM of 9 to 12 mice per sex/group. ^∗^*p* \< 0.05 versus the respective vehicle group (two tailed Student's *t*-test).](fphar-08-00743-g001){#F1}

Chronic Treatment with Fluoxetine Reduces the Expression of HDAC2 in DRG of Female Mice
---------------------------------------------------------------------------------------

Fluoxetine is known to induce direct epigenetic modification including increased levels of acetylated histone H3 and H4 proteins ([@B82]). Moreover, HDAC2 levels have been shown to be reduced after chronic fluoxetine in the brain ([@B28]). Thus, we investigated whether HDAC2 levels are modified in the DRG after a chronic treatment with fluoxetine in male and female mice. After a 21-day treatment with fluoxetine (10 mg/kg, i.p.), L4--L6 DRGs were removed and processed for protein analysis. As reported in **Figure [2](#F2){ref-type="fig"}**, western blot analysis shows that levels of HDAC2 were significantly decreased only in female mice (**Figure [2B](#F2){ref-type="fig"}**) whereas no changes were observed in male mice (**Figure [2A](#F2){ref-type="fig"}**) indicating that chronic fluoxetine is able to reduce the expression of HDAC2 in a sex-specific manner.

![Expression of HDAC2 in the L4-L5 DRGs of male and female mice after chronic administration with fluoxetine. Chronic administration with fluoxetine (10 mg/Kg, i.p. for 21 days) selectively decreased the expression of HDAC2 in DRGs from female mice **(B)** but not in male mice **(A)**. (Upper panels) Representative western blot analysis for HDAC2 in DRGs. (Lower panels) Densitometric analysis of HDAC2 bands normalized by actin. Data are the means ± SEM of five animals. ^∗^*p* \< 0.05 (Student's *t*-test) versus values obtained in animals of the same sex treated with vehicle.](fphar-08-00743-g002){#F2}

Effects of Chronic Treatment with Fluoxetine on HDAC2 and mGlu2 Receptor Expression in the Spinal DH of Male and Female Mice
----------------------------------------------------------------------------------------------------------------------------

By removing acetyl groups from histone proteins, HDACs promote an inactive state of chromatin resulting in the silencing of downstream genes. In particular, HDAC2 has been associated with a suppression on GRM2 gene encoding for the mGlu2 receptor ([@B48]).

We combined immunohistochemistry and western blot analyses in order to evaluate whether HDAC2 expression is affected in the spinal dorsal horn of male and female mice after a 21-day treatment with fluoxetine (10 mg/kg, i.p.). Also, since the expression of mGlu2 receptor has been reported to be under the control of HDAC2 ([@B48]), we tested whether mGlu2 receptor expression is affected by chronic treatment with fluoxetine.

As reported in **Figure [3](#F3){ref-type="fig"}**, no changes in HDAC2 expression were observed in male mice treated with fluoxetine (**Figures [3A,B](#F3){ref-type="fig"}**). Also no changes were detected in mGlu2 receptor expression in male mice (**Figure [3C](#F3){ref-type="fig"}**). Strikingly, a decrease in HDAC2 expression together with an increase in the expression of mGlu2 receptors was observed in female mice chronically treated with fluoxetine compared to vehicle treated female mice (**Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**).

![Expression of HDAC2 and mGlu2 receptors in the lumbar dorsal horn of male and female mice after chronic administration with fluoxetine. **(A,D)** Representative examples of HADC2 positive cells (left column) and mGlu2 immunostaining (central column) or overlapping (right column) in the dorsal horn of the spinal cord in male and female mice after chronic treatment with fluoxetine. **(B,E)** Quantification of the cell density (cell number/area) for HDAC2 immunopositive cells. Bars represent average ± SEM. ^∗^*p* \< 0.05 (Student's *t*-test) versus vehicle. **(C,F)** Densitometric analysis of mGlu2 bands normalized by actin. Data are the means ± SEM of five animals. ^∗^*p* \< 0.05 (Student's *t*-test) versus values obtained in animals of the same sex treated with vehicle.](fphar-08-00743-g003){#F3}

Effects of Chronic Treatment with Fluoxetine on Acetyl-Histone 3 Levels in the Spinal DH of Male and Female Mice
----------------------------------------------------------------------------------------------------------------

Since HDACs remove acetyl groups from histone proteins, we investigated whether the downregulation of HDAC2 affected levels of acetyl-H3 in the dorsal horn of the spinal cord. As expected, immunohistochemisty analysis in the spinal DH shows that chronic fluoxetine increases levels of acetyl-H3 specifically in female mice (**Figures [4C,D](#F4){ref-type="fig"}**) whereas no changes were observed in male mice (**Figures [4A,B](#F4){ref-type="fig"}**). This result is consistent with the reduced expression of HDAC2 in female mice (**Figures [3D,E](#F3){ref-type="fig"}**).

![Modulation of acetyl-H3 positive cell density in the dorsal horn of male and female mice by chronic treatment with fluoxetine. **(A,C)** Representative examples of acetyl-H3 immunopositive cells in the mouse dorsal horn from male and female mice treated with vehicle or fluoxetine (10 mg/kg, i.p.) for 21 days. **(B,D)** Quantification of immunopositive cells. Bars represent average ± SEM of three animals. ^∗^*p* \< 0.01 (Student's *t*-test) versus values obtained in animals of the same sex treated with vehicle.](fphar-08-00743-g004){#F4}

Discussion
==========

Several studies have shown gender differences in antidepressant efficacy ([@B45]) and a number of clinical studies have reported that depressed women respond to SSRIs therapy better than males ([@B37]; [@B46]; [@B67]; [@B9]). Although hormonal and pharmacokintec differences have been postulated as likely candidates to explain different responses to antidepressant pharmacotherapy between sex, the underlying mechanisms are still unknown ([@B78]).

Differences in pain sensitivity are also seen in women that usually report greater pain than men ([@B81]; [@B8]; [@B68]; [@B29]) and antidepressants are effective in relieving chronic pain ([@B33]). However, little is known about sex differences in response to chronic antidepressant treatment for the management of chronic pain. Moreover, although it is believed that depression can exacerbate pain, there is evidence that the antidepressant and the analgesic effects occur independently. Antidepressants are analgesic in patients with chronic pain and no concomitant depression ([@B69], [@B70]). In addition, the delay of action of antidepressants in chronic pain management in some studies is shorter than in depression ([@B3]). This work shows for the first time that chronic administration of fluoxetine induces sex-dependend analgesic effects in mice. We also observed sex-specific changes in mGlu2 expression in the DH and DRGs of female mice together with a decreased expression of HDAC2.

Metabotropic glutamate receptors are known to modulate pain sensitivity ([@B21]; [@B65]; [@B18]). In particular analgesia can be obtained by either blocking group I mGlu receptors, namely mGlu1 and mGlu5 ([@B83]; [@B71]; [@B7]; [@B13]) or by activating group II and group III mGlu receptors ([@B21]; [@B18]; [@B40]). Also, we have demonstrated that epigenetic drugs that increase the expression of mGlu2 receptors are analgesic in models of persistent pain ([@B19], [@B22], [@B20]; [@B90]).

Antidepressant drugs are known to induce analgesic effects. Different mechanisms have been demonstrated to explain their efficacy in reducing pain. However, long term regulation of gene expression and epigenetic mechanisms are likely to occur after chronic administration. In this regard, it is important to mention that different classes of antidepressant drugs have been demonstrated to have a plethora of effects in CNS disorders and are also known to have a role in neurogenesis ([@B85]; [@B53]; [@B56]; [@B95]; [@B44]). Many of these effects are sex-dependent ([@B35]; [@B45]) and fluoxetine itself is known to induce sex specific effects on neurogenesis ([@B38]). However, so far, no studies have investigated whether long-term treatment with antidepressant drugs affect pain behavior in a sex-dependent manner.

With this study we have shown that chronically administered fluoxetine induces sex-specific analgesic effects in the mouse formalin test and modulates the expression of the epigenetic modifying enzymes, HDAC2, and the expression of mGlu2 receptors in the spinal dorsal horn and DRG of female mice.

A number of HDAC inhibitors have been tested in different pain models and it has been shown that they have analgesic effects through different mechanisms ([@B22], [@B20]; [@B5]; [@B91]; [@B25]; [@B54]; [@B64]; [@B88]; [@B17]; [@B47]; [@B90]; [@B16]; [@B15]; [@B79]; [@B1]; [@B32]; [@B49]). We first demonstrated that HDAC inhibitors have analgesic properties via the upregulation of the metabotropic glutamate receptor type-2 ([@B22], [@B20]; [@B64]), an inhibitory receptor whose activation or upregulation mediates analgesia ([@B19], [@B22], [@B20]; [@B64]; [@B90]; [@B18]). More recently, the isoform HDAC2 has been involved both in pain modulation ([@B42]; [@B92]; [@B89]; [@B52]) and in the regulation of mGlu2 promoter activity ([@B48]) and fluoxetine itself has been reported to regulate the expression of the HDAC2 isoform ([@B28]).

In our experimental protocol we did not find sex differences in the formalin test in saline treated mice. Previous studies have reported sex differences in the mouse formalin test only in a late phase, phase 3, developing after 1 h of formalin injection, but not in phases 1 and 2 as observed in the present study ([@B43]). However, in pain studies phase 3 is rarely measured as it is considered less reproducible and relevant than phases 1 and 2 that reflect acute and tonic phase of pain, respectively ([@B23]; [@B80]). Consistent with our findings, the lack of analgesic effect of chronically injected fluoxetine in male mice has been previously reported in a persistent pain model such as the sciatic nerve cuffing in mice, where, similarly to clinical observations, TCAs such as amitriptyline and nortriptyline were able to elicit analgesic effects while fluoxetine resulted ineffective ([@B6]). Hormonal and genetic factors might influence pain sensitivity and the response to specific pharmacological treatments. Also, pharmacokinetic differences may account for the analgesic effects of fluoxetine in female mice. Female mice are known to metabolize fluoxetine and to produce more norfluoxetine than males in the brain ([@B38]). On the other hand norfluoxetine has been shown to interact with estrogen receptors to regulate ER-mediated gene expression ([@B50]). Furthermore, estradiol is able to reduce the expression of HDAC2 in the hippocampus ([@B93]).

Conclusion
==========

In summary, this study provides evidence that antidepressant drugs might have sex-specific analgesic effects after chronic administration. The observation that fluoxetine induces sex specific changes in HDAC2 and mGlu2 expression in the dorsal horn of the spinal cord and in DRGs provides a molecular explanation for the analgesic effects in females and suggests that estrogens and/or estrogen receptors might play a role in the observed effects. Studies in ovariectomized female mice and estrogen replacement protocols are in progress to investigate mechanisms underlying the observed differences in male and female mice in response to a chronic treatment with fluoxetine. So far we hypothesize that fluoxetine induces analgesic effects in female mice by reducing the expression of HDAC2 and consequently upregulating the mGlu2 receptor, known to induce analgesia.

Materials and Methods {#s1}
=====================

Animals
-------

Male and female CD1 mice littermates aged between 8 and 12 weeks were used for these experiments. All experiments were done in accordance with experimental protocols approved by the animal study committee at University of Catania, Italy (IACUC project 161/2012).

Drugs
-----

The dose of fluoxetine was chosen according to previous studies ([@B76]; [@B39]; [@B41]; [@B94]). In addition, we performed preliminary studies to identify a dose that produced analgesic effects without causing toxicity or motor impairment. To evaluate the effects of chronic administration of fluoxetine (10 mg/kg; Tocris) on acute and persistent pain, mice were randomly assigned to different groups by an independent researcher and intraperitoneally injected with vehicle (saline, 1 ml/kg) or fluoxetine (10 mg/kg) for 21 consecutive days.

Behavioral Experiments
----------------------

Littermate male and female mice aged between 8 and 9 weeks were acclimated to the experimental room and were used for behavioral tests by observers blind to the sex and the treatment of the animals.

Formalin Test
-------------

Formalin (5%, 10 μl; Sigma--Aldrich) was injected subcutaneously into the plantar surface of the right hind paw, and the total time spent licking and flinching the injected paw was monitored for 1 h and recorded every 5 min as reported previously ([@B22]). Formalin scores were separated into two phases, phase I (0--10 min) and phase II (15--50 min). A mean response was then calculated for each phase. All tests were performed and analyzed blind to treatment.

Immunohystochemical Staining
----------------------------

After the behavioral test mice were euthanized by CO~2~ inhalation and spinal cord was removed and kept in 4% paraformaldehyde at 4°C overnight and then in 30% sucrose for cryoprotection. Sections (20 μm thick) from the lumbar segment were sequentially collected using a sliding microtome and stored at -20°C in an anti freezer solution containing 30% ethylene glycol in 0.1 M phosphate buffer (PBS). For immunohystochemical staining, spinal cord sections from the lumbar segment were sequentially incubated with rabbit anti-HDAC2 (1:200, Abcam) and mouse anti-mGlu2 (1:250 Abcam) in PBS containing 3% bovine serum albumin (BSA, Sigma) and 0.1% Triton X-100 overnight. The following fluorescent secondary antibodies were used: donkey anti-rabbit (1:200; Jackson Immuno Research) for 2 h, and Cy3-conjugated streptavidin (1:1000; Jackson Immuno Research) for 1 h. After washing with PBS, sections were coverslipped with a mounting medium for fluorescence (Sigma). Fluorescent signal was detected using a Zeiss Axio Observer.Z1 microscope equipped with the Apotome.2 acquisition system (Carl Zeiss S.p.A, Milan, Italy).

Quantification and colocalization of positive cells in the dorsal horn were performed by an investigator blind to the treatment using Image-J software. At least three fields per slices from five slices per animals were analyzed. Three different mice/group were used. Statistical analysis was performed by using Student's *t*-test comparing treatment versus vehicle in animals of the same sex.

Western Blot
------------

Mice were euthanized by CO~2~ inhalation and L5--L6 dorsal root ganglia and the lumbar segment of the spinal cord of male and female CD1 mice were removed and homogenized. Ten micrograms of total protein were separated by 10% SDS-PAGE and electrophoretically transferred onto protein-sensitive PVDF transfer membranes (Thermo Scientific). Membranes were blocked in Odyssey blocker (LI-COR) for 1 h at room temperature and rabbit anti-HDAC2 (1:1000, Abcam), mouse anti-mGlu2 (1:1000, Abcam) or mouse anti-actin (1:1000, Sigma--Aldrich) primary antibody were simultaneously used for immunoblotting overnight at 4°C. A goat anti-rabbit antibody labeled with IRD800CW and a goat anti-mouse antibody labeled with Alexa 680 (LICOR) were incubated for 1 h at room temperature. Proteins were detected with the Odyssey Infrared Fluorescence Imaging System (LI-COR) and protein quantification was expressed as integrated intensity.

Statistical Analysis
--------------------

Sample size was calculated with the GPower software. *A priori* analysis was performed by *F*-test (ANOVA) with the following input parameters: alpha = 0.05, power 1-beta = 0.95, *F* = 0,40 resulting in a total sample size of 56 mice. Behavioral data are presented as mean ± SEM of at least nine animals per group. Statistical comparisons were performed with Student's *t*-test using the statistical software package GraphPad Prism. Western blot and immunochemical analyses are presented as mean ± SEM of at least three independent experiments performed in triplicate. Statistical significance was determined using unpaired *t*-tests. In all cases, *p* \< 0.05 was considered statistically significant.
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